AdvanDx

AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for identifying pathogens that cause serious infections in hospitalized patients. Its mission is to help healthcare providers optimize antibiotic therapy earlier to improve patient outcomes while limiting unnecessary antibiotic use and reducing hospital costs.AdvanDx employs a unique Whole Cell Analysis (WCA) approach using its proprietary Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA FISH) technology platform for pathogen identification. This technology enables rapid, highly accurate single-cell analysis of species, resistance, and virulence markers of bacterial cells found in samples from patients with severe infections.AdvanDx is the market leader in molecular testing for positive blood cultures, enabling clinical microbiology laboratories to report pathogen identification results 48 to 72 hours earlier than traditional methods. When used by physicians and pharmacists to ensure early and appropriate antibiotic treatment for patients with bloodstream infections (also known as sepsis), AdvanDx's PNA FISH® tests have been shown in clinical studies to reduce patient mortality, shorten length of stay (LOS), and lower hospitalization costs.